These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

224 related articles for article (PubMed ID: 11374668)

  • 21. AMACR immunostaining is useful in detecting dysplastic epithelium in Barrett's esophagus, ulcerative colitis, and Crohn's disease.
    Dorer R; Odze RD
    Am J Surg Pathol; 2006 Jul; 30(7):871-7. PubMed ID: 16819330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DNA abnormalities as marker of risk for progression of Barrett's esophagus to adenocarcinoma: image cytometric DNA analysis in formalin-fixed tissues.
    Fang M; Lew E; Klein M; Sebo T; Su Y; Goyal R
    Am J Gastroenterol; 2004 Oct; 99(10):1887-94. PubMed ID: 15447746
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Molecular evaluation of ablative therapy of Barrett's oesophagus.
    Hage M; Siersema PD; Vissers KJ; Steyerberg EW; Haringsma J; Kuipers EJ; van Dekken H
    J Pathol; 2005 Jan; 205(1):57-64. PubMed ID: 15586364
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Risk stratification of Barrett's esophagus: updated prospective multivariate analysis.
    Weston AP; Sharma P; Mathur S; Banerjee S; Jafri AK; Cherian R; McGregor D; Hassanein RS; Hall M
    Am J Gastroenterol; 2004 Sep; 99(9):1657-66. PubMed ID: 15330898
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Complete Barrett's eradication endoscopic mucosal resection: an effective treatment modality for high-grade dysplasia and intramucosal carcinoma--an American single-center experience.
    Chennat J; Konda VJ; Ross AS; de Tejada AH; Noffsinger A; Hart J; Lin S; Ferguson MK; Posner MC; Waxman I
    Am J Gastroenterol; 2009 Nov; 104(11):2684-92. PubMed ID: 19690526
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical use of p53 in Barrett's esophagus.
    Keswani RN; Noffsinger A; Waxman I; Bissonnette M
    Cancer Epidemiol Biomarkers Prev; 2006 Jul; 15(7):1243-9. PubMed ID: 16835318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mucin core polypeptide expression in the progression of neoplasia in Barrett's esophagus.
    Glickman JN; Blount PL; Sanchez CA; Cowan DS; Wongsurawat VJ; Reid BJ; Odze RD
    Hum Pathol; 2006 Oct; 37(10):1304-15. PubMed ID: 16949933
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Dysplasia and risk of further neoplastic progression in a regional Veterans Administration Barrett's cohort.
    Dulai GS; Shekelle PG; Jensen DM; Spiegel BM; Chen J; Oh D; Kahn KL
    Am J Gastroenterol; 2005 Apr; 100(4):775-83. PubMed ID: 15784018
    [TBL] [Abstract][Full Text] [Related]  

  • 29. P53 mutational status improves estimation of prognosis in patients with curatively resected adenocarcinoma in Barrett's esophagus.
    Schneider PM; Stoeltzing O; Roth JA; Hoelscher AH; Wegerer S; Mizumoto S; Becker K; Dittler HJ; Fink U; Siewert JR
    Clin Cancer Res; 2000 Aug; 6(8):3153-8. PubMed ID: 10955797
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Outcomes of dysplasia arising in Barrett's esophagus: a dynamic view.
    Romagnoli R; Collard JM; Gutschow C; Yamusah N; Salizzoni M
    J Am Coll Surg; 2003 Sep; 197(3):365-71. PubMed ID: 12946790
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Accumulation of p53 protein in normal, dysplastic, and neoplastic Barrett's oesophagus.
    Krishnadath KK; Tilanus HW; van Blankenstein M; Bosman FT; Mulder AH
    J Pathol; 1995 Feb; 175(2):175-80. PubMed ID: 7738712
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effect of proton pump inhibitors on markers of risk for high-grade dysplasia and oesophageal cancer in Barrett's oesophagus.
    Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
    Aliment Pharmacol Ther; 2008 Feb; 27(4):321-6. PubMed ID: 18047565
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Are ulcers a marker for invasive carcinoma in Barrett's esophagus? Data from a diagnostic variability study with clinical follow-up.
    Montgomery E; Bronner MP; Greenson JK; Haber MM; Hart J; Lamps LW; Lauwers GY; Lazenby AJ; Lewin DN; Robert ME; Washington K; Goldblum JR
    Am J Gastroenterol; 2002 Jan; 97(1):27-31. PubMed ID: 11808966
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Risk of malignant progression in Barrett's esophagus indefinite for dysplasia.
    Ma M; Shroff S; Feldman M; DeMarshall M; Price C; Tierney A; Falk GW
    Dis Esophagus; 2017 Mar; 30(3):1-5. PubMed ID: 28184470
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Barrett's dysplasia and the Vienna classification: reproducibility, prediction of progression and impact of consensus reporting and p53 immunohistochemistry.
    Kaye PV; Haider SA; Ilyas M; James PD; Soomro I; Faisal W; Catton J; Parsons SL; Ragunath K
    Histopathology; 2009 May; 54(6):699-712. PubMed ID: 19438745
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An open-label, prospective trial of cryospray ablation for Barrett's esophagus high-grade dysplasia and early esophageal cancer in high-risk patients.
    Dumot JA; Vargo JJ; Falk GW; Frey L; Lopez R; Rice TW
    Gastrointest Endosc; 2009 Oct; 70(4):635-44. PubMed ID: 19559428
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Barrett's esophagus: a retrospective analysis of 13 years surveillance.
    Switzer-Taylor V; Schlup M; Lübcke R; Livingstone V; Schultz M
    J Gastroenterol Hepatol; 2008 Sep; 23(9):1362-7. PubMed ID: 18205769
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of survivin, p53, and caspase 3 in Barrett's esophagus carcinogenesis.
    Parenti A; Leo G; Porzionato A; Zaninotto G; Rosato A; Ninfo V
    Hum Pathol; 2006 Jan; 37(1):16-22. PubMed ID: 16360411
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Long-term follow-up of complete Barrett's eradication endoscopic mucosal resection (CBE-EMR) for the treatment of high grade dysplasia and intramucosal carcinoma.
    Larghi A; Lightdale CJ; Ross AS; Fedi P; Hart J; Rotterdam H; Noffsinger A; Memeo L; Bhagat G; Waxman I
    Endoscopy; 2007 Dec; 39(12):1086-91. PubMed ID: 17701854
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Advanced pathology under squamous epithelium on initial EMR specimens in patients with Barrett's esophagus and high-grade dysplasia or intramucosal carcinoma: implications for surveillance and endotherapy management.
    Chennat J; Ross AS; Konda VJ; Lin S; Noffsinger A; Hart J; Waxman I
    Gastrointest Endosc; 2009 Sep; 70(3):417-21. PubMed ID: 19555948
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.